Arena Shares Full Data Supporting Etrasimod’s Long-term Safety and Efficacy
News
Arena Pharmaceuticals announced full long-term results of its OASIS extension study, confirming that once-daily oral etrasimod leads to sustained clinical responses and favorable safety for up to 46 weeks in ... Read more